Drug-coated balloon for femoropopliteal in-stent restenosis: current research progress
Author:
Affiliation:

Clc Number:

R654.3

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    In-stent restenosis (ISR) is the common clinical problem in treatment of peripheral vascular diseases. However, there is no uniform and effective interventional method for ISR at present. Drug-coated balloon (DCB) provides a new strategy in treatment of femoropopliteal ISR and some preliminary attempts have been done in recent years. For ISR, DCB has higher patency rate and lower target lesion revascularization rate at postoperative 6 months and even 1 year compared with common balloon, but its long-term efficacy still needs further verification. Studies demonstrated that long segment stenosis in the stent or in the lumen of occlusive disease have higher rate of recurrent stenosis. The combination of DCB and debulking technique has been given great expectation, but it currently lacks enough study results. Besides, for femoropopliteal ISR, no study comparing the effects between DCB and new metal stent, drug-eluting stent or covered stent and so on has been performed as yet, and whether the combination of DCB with those techniques will bring better results is not clear. Thus, more high-quality randomized controlled trials are urgently needed to answer these questions.

    Reference
    Related
    Cited by
Get Citation

LIU Junchao, WANG Bing. Drug-coated balloon for femoropopliteal in-stent restenosis: current research progress[J]. Chin J Gen Surg,2016,25(12):1796-1800.
DOI:10.3978/j. issn.1005-6947.2016.12.021

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:September 13,2016
  • Revised:November 16,2016
  • Adopted:
  • Online: December 15,2016
  • Published: